Published: Sun, November 22, 2020
Medical | By

Oxford researcher expects coronavirus vaccine results by Christmas

Oxford researcher expects coronavirus vaccine results by Christmas

ChAdOx1 nCov-2019 vaccine is now undergoing its Phase 3 trial with 40,051 participants now enrolled.

The findings were published on Thursday in The Lancet.

WATCH | How well will COVID-19 vaccines work in the real world?

As companies around the world race to develop coronavirus vaccines, hundreds of thousands of people in China were inoculated with a vaccine before its efficacy was proven in trials.

From the earlier phase data, researchers found that younger participants experienced side effects like pain at the vaccine's injection site, fever and muscle ache more often than older adults.

About 42% of global participants and 30% of United States participants in the Phase 3 study have racially and ethnically diverse backgrounds, the companies said in a news release, and 41% of global and 45% of U.S. participants are ages 56 to 85. "We just don't know", she adds.

The U.S. Food and Drug Administration's outside advisers will meet on December 10 to discuss whether to authorize the COVID-19 vaccine developed by Pfizer Inc PFE.N and German partner BioNTech 22UAy.DE for emergency use, the agency said on Friday. While CoronaVac was produced with tried-and-true methods, the mRNA technology is new, and there hasn't been an mRNA vaccine approved by the Food and Drug Administration before.

Commenting on the findings, Zhu Fengcai, one of the authors of the paper, said: "Our findings show that CoronaVac is capable of inducing a quick antibody response within four weeks of immunisation by giving two doses of the vaccine at a 14-day interval". In comparison, Moderna and Pfizer reported the same or higher antibody levels for their mRNA vaccines than those in recovered patients.

Sinovac is now running three phase three trials - in Indonesia, Brazil and Turkey. Indonesia is reportedly aiming to roll out the vaccine by the end of the year.

"It is essential that a COVID-19 vaccine can be effective across a broad age range, particularly in older individuals where they are disproportionately at risk of severe COVID-19 disease".

Moderna will charge governments between $25 and $37 per dose of its Covid-19 vaccine candidate, depending on the amount ordered, Chief Executive Stephane Bancel told German weekly "Welt am Sonntag" (WamS). "It would just be logistically very hard to transport [an mRNA] vaccine at the cold and ultra-cold temperatures that are required", he adds. "But nonetheless, the more vaccine globally, the better, assuming that it's safe and effective".

Like this: